Cancer Incidence Projections to 2035 in Northern Ireland


Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2015 The Authors

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Cancer incidence trends 1993-2013 with projections to 2035

David Donnelly1 & Anna Gavin1

NI Cancer Registry Centre for Public Health, Mulhouse Building, Gowerston Road, Belfast BT12 6DP

Methods

Data on all cancers (excluding NMSC) diagnosed during 1993-2013 was extracted from the NI Cancer Registry. Age-specific rates for all cancers combined and 30 common cancers were determined for both sexes by year of diagnosis. The data was fitted separately for ages 0-49, 50-59, 60-69, 70-79 and 80+ using a regression model with five-year age group, five-year birth cohort and year of diagnosis used as predictors of the cancer incidence rate. The resulting model was used to predict rates in future years, which were combined with population projections to provide estimates of the future number of cases.

PROJECTED NUMBER OF CASES DIAGNOSED FROM 2015 TO 2035

In 2009-2013 there were 4,347 male and 4,275 female cases of cancer (ex. NMSC) diagnosed each year.

By 2020 the number of cases is expected to rise by 25% for men and by 24% for women to 5,443 male and 5,285 female cases.

By 2035 the number of cases is expected to rise by 65% for men and by 63% for women to 7,181 male and 6,967 female cases.

PROJECTED CHANGE IN INCIDENCE RATES BY SEX AND TYPE

Compared to the 2009-2013 average male incidence rates are projected to:
- decrease by more than 20% by 2035 for stomach, bladder and prostate cancers,
- increase by more than 20% by 2035 for melanoma, oral, liver and kidney cancers.

Also compared to the 2009-2013 average female incidence rates are projected to:
- decrease by more than 20% by 2035 for stomach and cervical cancers;
- increase by more than 20% by 2035 for melanoma, oral, uterine, liver, kidney, pancreatic, lung and breast cancer.

FACTORS THAT CAN INFLUENCE INCIDENCE PROJECTIONS

Changes to risk factor exposure within the general population.
Risk factors likely to have the greatest impact on future projections are:
- Tobacco use;
- Excessive alcohol consumption;
- Obesity, lack of physical activity and/or lack of a balanced diet;
- Ultraviolet radiation from sunshine or sun beds.

Introduction of health service initiatives that aim to either prevent or diagnose cancer early.
These include vaccinations (e.g. the HPV vaccination), screening (e.g. the breast, cervical and colorectal screening programmes) and diagnostic tests (e.g. PSA testing for prostate cancer).

Changes to cancer classification or revisions to population projections.

NIH: Non-Hodgkin’s Lymphoma, NMSC: Non-melanoma skin cancer

CONCLUSION: The increasing number of cancer cases will result in an increased burden on health services. However the largest increases are projected for cancers such as melanoma that are largely preventable. The opportunity thus exists to reduce the projected increase through preventative measures.

Acknowledgements
The NI Cancer Registry is funded by the Public Health Agency

PROJECTED NUMBER OF CASES DIAGNOSED FROM SEX AND TYPE IN 2020 AND 2035

The number of cases diagnosed each year is projected to increase for all cancer types, except for stomach cancer, and cervical cancer.

By 2035 case volume is expected to more than double for liver, kidney and oral cancers, for female uterine and pancreatic cancers and for male melanoma.

NIH: Non-Hodgkin’s Lymphoma, NMSC: Non-melanoma skin cancer